USFDA inspection at Cipla Ltd's manufacturing facility in Verna, Goa, India

Pursuant to the routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI) at Company's manufacturing facility in Verna, Goa, India between 6th to 17th April 2026, the United States Food and Drug Administration (USFDA) vide communication dated 10th June 2026 (2217 hours IST) has classified the above referred inspection as Voluntary Action Indicated (VAI).

Shares of Cipla Limited was last trading in BSE at Rs. 1383.00 as compared to the previous close of Rs. 1376.25. The total number of shares traded during the day was 67540 in over 2880 trades.

The stock hit an intraday high of Rs. 1390.70 and intraday low of 1370.15. The net turnover during the day was Rs. 93676224.00.

Source : Equity Bulls

Keywords

Cipla INE059A01026 Pharmaceuticals USFDA Inspection ManufacturingFacility Verana Goa